Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

Evaluation of the predictive value of the bleeding prediction score VTE-BLEED for recurrent venous thromboembolism.

Klok FA, Presles E, Tromeur C, Barco S, Konstantinides SV, Sanchez O, Pernod G, Raj L, Robin P, Le Roux PY, Hoffman C, Mélac S, Bertoletti L, Girard P, Laporte S, Mismetti P, Meyer G, Leroyer C, Couturaud F; PADIS‐PE Investigators.

Res Pract Thromb Haemost. 2019 May 25;3(3):364-371. doi: 10.1002/rth2.12214. eCollection 2019 Jul.

PMID:
31294323
Free PMC Article
2.

[Recommendations for best practice in the management of venous thromboembolic disease in adults. Long version].

Sanchez O, Benhamou Y, Bertoletti L, Constans J, Couturaud F, Delluc A, Elias A, Fischer AM, Frappé P, Gendron N, Girard P, Godier A, Gut-Gobert C, Laporte S, Mahé I, Mauge L, Meneveau N, Meyer G, Mismetti P, Parent F, Pernod G, Quéré I, Revel MP, Roy PM, Salaün PY, Smadja DM, Sevestre MA.

Rev Mal Respir. 2019 Jul 4. pii: S0761-8425(19)30210-4. doi: 10.1016/j.rmr.2019.05.038. [Epub ahead of print] French. No abstract available.

PMID:
31280989
3.

Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS.

Blin P, Dureau-Pournin C, Bénichou J, Cottin Y, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N.

Am J Cardiovasc Drugs. 2019 Jun 29. doi: 10.1007/s40256-019-00359-z. [Epub ahead of print]

PMID:
31254174
4.

Predictors for Residual Pulmonary Vascular Obstruction after Unprovoked Pulmonary Embolism: Implications for Clinical Practice-The PADIS-PE Trial.

Raj L, Robin P, Le Mao R, Presles E, Tromeur C, Sanchez O, Pernod G, Bertoletti L, Jego P, Leven F, Lemarié CA, Martin A, Planquette B, Le Roux PY, Salaun PY, Nonent M, Girard P, Lacut K, Melac S, Mismetti P, Laporte S, Meyer G, Leroyer C, Couturaud F; PADIS-PE Investigators.

Thromb Haemost. 2019 Jun 23. doi: 10.1055/s-0039-1692424. [Epub ahead of print]

PMID:
31230343
5.

Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability.

Siguret V, Abdoul J, Delavenne X, Curis E, Carlo A, Blanchard A, Salem JE, Gaussem P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA, Lecompte T, Gouin-Thibault I.

J Thromb Haemost. 2019 Jun 19. doi: 10.1111/jth.14541. [Epub ahead of print]

PMID:
31215111
6.

High tolerance of progressive elastic compression in peripheral arterial disease.

Couzan S, Pouget JF, Le Hello C, Chapelle C, Laporte S, Mismetti P.

Vasa. 2019 Jun 4:1-5. doi: 10.1024/0301-1526/a000799. [Epub ahead of print]

7.

Direct oral anticoagulants are associated with limited damage of endothelial cells of the blood-brain barrier mediated by the thrombin/PAR-1 pathway.

Puech C, Delavenne X, He Z, Forest V, Mismetti P, Perek N.

Brain Res. 2019 Sep 15;1719:57-63. doi: 10.1016/j.brainres.2019.05.024. Epub 2019 May 20.

PMID:
31121158
8.

Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries.

Chuang LH, Gumbs P, van Hout B, Agnelli G, Kroep S, Monreal M, Bauersachs R, Willich SN, Gitt A, Mismetti P, Cohen A, Jimenez D.

Qual Life Res. 2019 Aug;28(8):2111-2124. doi: 10.1007/s11136-019-02175-z. Epub 2019 Apr 4.

9.

Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study.

Ten Cate V, Lensing AW, Weitz JI, Beyer-Westendorf J, Wells PS, Mismetti P, Prandoni P, Cohen AT, Davidson BL, Prins MH.

Haematologica. 2019 Mar 7. pii: haematol.2018.209924. doi: 10.3324/haematol.2018.209924. [Epub ahead of print]

10.

[Recommendations of good practice for the management of thromboembolic venous disease in adults. Short version].

Sanchez O, Benhamou Y, Bertoletti L, Constant J, Couturaud F, Delluc A, Elias A, Fischer AM, Frappé P, Gendron N, Girard P, Godier A, Gut-Gobert C, Laporte S, Mahé I, Mauge L, Meneveau N, Meyer G, Mismetti P, Parent F, Pernod G, Quéré I, Revel MP, Roy PM, Salaün PY, Smadja DM, Sevestre MA.

Rev Mal Respir. 2019 Feb;36(2):249-283. doi: 10.1016/j.rmr.2019.01.003. Epub 2019 Feb 22. French. No abstract available.

PMID:
30799126
11.

Effects of heparin and derivatives on podocytes: An in vitro functional and morphological evaluation.

Delézay O, Hé Z, Sabido O, Hodin S, Bin V, Saleem MA, Mismetti P, Delavenne X.

J Cell Physiol. 2019 Jan 26. doi: 10.1002/jcp.28191. [Epub ahead of print]

PMID:
30684278
12.

Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial.

Couturaud F, Pernod G, Presles E, Duhamel E, Jego P, Provost K, Pan-Petesch B, Sollier CBD, Tromeur C, Hoffmann C, Bressollette L, Lorillon P, Girard P, Le Moigne E, Le Hir A, Guégan M, Laporte S, Mismetti P, Lacut K, Bosson JL, Bertoletti L, Sanchez O, Meyer G, Leroyer C, Mottier D; “PADIS-DVT” investigators.

Haematologica. 2019 Jul;104(7):1493-1501. doi: 10.3324/haematol.2018.210971. Epub 2019 Jan 3.

13.

Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study.

Blin P, Samama CM, Sautet A, Benichou J, Lignot-Maleyran S, Lamarque S, Lorrain S, Lassalle R, Droz-Perroteau C, Mismetti P, Moore N.

Pharmacol Res. 2019 Mar;141:201-207. doi: 10.1016/j.phrs.2018.12.018. Epub 2018 Dec 21.

PMID:
30583081
14.

Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation.

Blin P, Dureau-Pournin C, Cottin Y, Bénichou J, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N.

Clin Pharmacol Ther. 2019 Jun;105(6):1439-1455. doi: 10.1002/cpt.1318. Epub 2019 Feb 6.

PMID:
30499605
15.

Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation.

Blin P, Dureau-Pournin C, Cottin Y, Bénichou J, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N.

Br J Clin Pharmacol. 2019 Feb;85(2):432-441. doi: 10.1111/bcp.13815. Epub 2018 Dec 16.

PMID:
30423205
16.

Management and outcome of major bleeding in patients receiving vitamin K antagonists for venous thromboembolism.

Moustafa F, Stehouwer A, Kamphuisen P, Sahuquillo JC, Sampériz Á, Alfonso M, Pace F, Suriñach JM, Blanco-Molina Á, Mismetti P, Monreal M; RIETE Investigators.

Thromb Res. 2018 Nov;171:74-80. doi: 10.1016/j.thromres.2018.09.049. Epub 2018 Sep 22.

PMID:
30265883
17.

Assessment of HBEC-5i endothelial cell line cultivated in astrocyte conditioned medium as a human blood-brain barrier model for ABC drug transport studies.

Puech C, Hodin S, Forest V, He Z, Mismetti P, Delavenne X, Perek N.

Int J Pharm. 2018 Nov 15;551(1-2):281-289. doi: 10.1016/j.ijpharm.2018.09.040. Epub 2018 Sep 18.

PMID:
30240829
18.

Role of platelet α2-adrenoreceptor in biological low response to Clopidogrel for patients with non cardioembolic ischemic stroke or transient ischemic attack.

Varvat J, Epinat M, Montmartin A, Accassat S, Boutet C, Garcin A, Li G, Malergue F, Chapelle C, Laporte S, Garnier P, Lambert C, Mallouk N, Mismetti P.

Am J Transl Res. 2018 Aug 15;10(8):2712-2721. eCollection 2018.

19.

Assessment of a flow cytometry technique for studying signaling pathways in platelets: Monitoring of VASP phosphorylation in clinical samples.

Mallouk N, Varvat J, Berger A, Epinat M, Accassat S, Garcin A, Montmartin A, Li G, Garnier P, Mismetti P, Lambert C.

Pract Lab Med. 2018 Feb 16;11:10-18. doi: 10.1016/j.plabm.2018.02.002. eCollection 2018 Jul.

20.

The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.

Ten Cate H, Lensing AWA, Weitz JI, Middeldorp S, Beyer-Westendorf J, Kubitza D, Brighton T, Raskob GE, Mismetti P, Prandoni P, Gebel M, Prins MH.

Thromb Res. 2018 Oct;170:75-83. doi: 10.1016/j.thromres.2018.08.008. Epub 2018 Aug 15.

PMID:
30121419
21.

Benefit of Risk Score-Guided Prophylaxis in Pregnant Women at Risk of Thrombotic Events: A Controlled Before-and-After Implementation Study.

Chauleur C, Gris JC, Laporte S, Chapelle C, Bertoletti L, Equy V, Gaucherand P, Bazan E, Dupuis O, Gallot D, Mismetti P; STRATHEGE Investigators and The STRATHEGE Group.

Thromb Haemost. 2018 Sep;118(9):1564-1571. doi: 10.1055/s-0038-1668524. Epub 2018 Aug 13.

PMID:
30103244
22.

Screening cancer after venous thromboembolism: How many abnormal tests before diagnosing cancer? An analysis of practice.

Duvillard C, De Magalhaes E, Moulin N, Accassat S, Mismetti P, Bertoletti L.

Presse Med. 2018 Jul - Aug;47(7-8 Pt 1):e99-e106. doi: 10.1016/j.lpm.2018.01.026. Epub 2018 Jul 31.

PMID:
30075951
23.

Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A time-to-event analysis.

Zufferey PJ, Ollier E, Delavenne X, Laporte S, Mismetti P, Duffull SB.

Br J Clin Pharmacol. 2018 Oct;84(10):2242-2251. doi: 10.1111/bcp.13663. Epub 2018 Jul 14.

PMID:
29877590
24.

Individualized PK-based prophylaxis in severe haemophilia.

Dargaud Y, Delavenne X, Hart DP, Meunier S, Mismetti P.

Haemophilia. 2018 Mar;24 Suppl 2:3-17. doi: 10.1111/hae.13397. Review.

PMID:
29543364
25.

Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events-a meta-analysis.

Trone JC, Ollier E, Chapelle C, Bertoletti L, Cucherat M, Mismetti P, Magné N, Laporte S.

Ann Oncol. 2018 Apr 1;29(4):803-811. doi: 10.1093/annonc/mdy035.

PMID:
29415169
26.

Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial.

Tromeur C, Sanchez O, Presles E, Pernod G, Bertoletti L, Jego P, Duhamel E, Provost K, Parent F, Robin P, Deloire L, Leven F, Mingant F, Bressollette L, Le Roux PY, Salaun PY, Nonent M, Pan-Petesch B, Planquette B, Girard P, Lacut K, Melac S, Mismetti P, Laporte S, Meyer G, Mottier D, Leroyer C, Couturaud F; PADIS-PE Investigators18.

Eur Respir J. 2018 Jan 4;51(1). pii: 1701202. doi: 10.1183/13993003.01202-2017. Print 2018 Jan.

27.

European guidelines on perioperative venous thromboembolism prophylaxis: Inferior vena cava filters.

Comes RF, Mismetti P, Afshari A; ESA VTE Guidelines Task Force.

Eur J Anaesthesiol. 2018 Feb;35(2):108-111. doi: 10.1097/EJA.0000000000000730.

PMID:
29112551
28.

Glomerular filtration drug injury: In vitro evaluation of functional and morphological podocyte perturbations.

Delézay O, He Z, Hodin S, Saleem MA, Mismetti P, Perek N, Delavenne X.

Exp Cell Res. 2017 Dec 15;361(2):300-307. doi: 10.1016/j.yexcr.2017.10.031. Epub 2017 Oct 31.

PMID:
29107066
29.

In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition.

Hodin S, Basset T, Jacqueroux E, Delezay O, Clotagatide A, Perek N, Mismetti P, Delavenne X.

Eur J Drug Metab Pharmacokinet. 2018 Apr;43(2):183-191. doi: 10.1007/s13318-017-0434-x.

PMID:
28895074
30.

The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry.

Bauersachs R, Agnelli G, Gitt AK, Monreal M, Mismetti P, Willich SN, Laeis P, Fronk EM, Bramlage P, Cohen AT; PREFER in VTE Scientific Steering Committee.

Thromb Res. 2017 Sep;157:181-188. doi: 10.1016/j.thromres.2017.07.029. Epub 2017 Jul 28.

PMID:
28780343
31.

The management of acute venous thromboembolism in clinical practice.

Cohen AT, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, Monreal M, Willich SN, Bramlage P, Agnelli G; PREFER in VTE Scientific Steering Committee and the PREFER in VTE Investigators.

Thromb Haemost. 2017 Jul;117(7):1326-1337. doi: 10.1160/TH16-10-0793. Epub 2017 Nov 28.

PMID:
30457158
32.

Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta-analysis of randomized controlled trials.

Laporte S, Chapelle C, Bertoletti L, Ollier E, Zufferey P, Lega JC, Merah A, Décousus H, Schulman S, Meyer G, Cucherat M, Mismetti P.

J Thromb Haemost. 2017 Aug;15(8):1547-1558. doi: 10.1111/jth.13740. Epub 2017 Jul 5. Review.

PMID:
28544422
33.

Pharmacokinetic/pharmacodynamic model for unfractionated heparin dosing during cardiopulmonary bypass.

Delavenne X, Ollier E, Chollet S, Sandri F, Lanoiselée J, Hodin S, Montmartin A, Fuzellier JF, Mismetti P, Gergelé L.

Br J Anaesth. 2017 May 1;118(5):705-712. doi: 10.1093/bja/aex044.

34.

The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.

Cohen AT, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, Monreal M, Willich SN, Bramlage P, Agnelli G, Prefer In Vte Scientific Steering Committee And The Prefer In Vte Investigators OBOT.

Thromb Haemost. 2017 Jun 27;117(7):1326-1337. doi: 10.1160/TH16-10-0793. Epub 2017 Apr 13.

35.

Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study.

Rodger MA, Le Gal G, Anderson DR, Schmidt J, Pernod G, Kahn SR, Righini M, Mismetti P, Kearon C, Meyer G, Elias A, Ramsay T, Ortel TL, Huisman MV, Kovacs MJ; REVERSE II Study Investigators.

BMJ. 2017 Mar 17;356:j1065. doi: 10.1136/bmj.j1065.

36.

Effect of Activated Charcoal on Rivaroxaban Complex Absorption.

Ollier E, Hodin S, Lanoiselée J, Escal J, Accassat S, De Magalhaes E, Basset T, Bertoletti L, Mismetti P, Delavenne X.

Clin Pharmacokinet. 2017 Jul;56(7):793-801. doi: 10.1007/s40262-016-0485-1.

PMID:
27910037
37.

Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin.

Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA.

J Thromb Haemost. 2017 Feb;15(2):273-283. doi: 10.1111/jth.13577. Epub 2017 Feb 6.

38.

Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) - September 2015.

Albaladejo P, Bonhomme F, Blais N, Collet JP, Faraoni D, Fontana P, Godier A, Llau J, Longrois D, Marret E, Mismetti P, Rosencher N, Roullet S, Samama CM, Schved JF, Sié P, Steib A, Susen S; French Working Group on Perioperative Hemostasis (GIHP).

Anaesth Crit Care Pain Med. 2017 Feb;36(1):73-76. doi: 10.1016/j.accpm.2016.09.002. Epub 2016 Sep 20.

39.

Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies.

Laporte S, Chapelle C, Caillet P, Beyens MN, Bellet F, Delavenne X, Mismetti P, Bertoletti L.

Pharmacol Res. 2017 Apr;118:19-32. doi: 10.1016/j.phrs.2016.08.017. Epub 2016 Aug 10.

PMID:
27521835
40.

Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism.

Bertoletti L, Ollier E, Duvillard C, Delavenne X, Beyens MN, De Magalhaes E, Bellet F, Basset T, Mismetti P, Laporte S.

Pharmacol Res. 2017 Apr;118:33-42. doi: 10.1016/j.phrs.2016.06.023. Epub 2016 Jun 24. Review.

PMID:
27350265
41.

Comparison of blood coagulation factors between patients with gastrointestinal or intracranial bleeding under vitamin K antagonists.

Moustafa F, Saint-Denis J, Laporte S, Mismetti P, Schmidt J.

Eur J Intern Med. 2016 Sep;33:e22-4. doi: 10.1016/j.ejim.2016.05.001. Epub 2016 May 18. No abstract available.

PMID:
27209417
42.

Treatment of pulmonary embolism.

Décousus H, Mismetti P, Couturaud F, Ageno W, Bauersachs R.

Presse Med. 2015 Dec;44(12 Pt 2):e393-9. doi: 10.1016/j.lpm.2015.10.008. Epub 2015 Nov 4. Review.

PMID:
26547678
43.

The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry.

Agnelli G, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, Monreal M, Willich SN, Wolf WP, Cohen AT; PREFER in VTE investigators.

Thromb J. 2015 Oct 21;13:41. doi: 10.1186/s12959-015-0071-z. eCollection 2015.

44.

In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors.

Ollier E, Hodin S, Basset T, Accassat S, Bertoletti L, Mismetti P, Delavenne X.

Fundam Clin Pharmacol. 2015 Dec;29(6):604-14. doi: 10.1111/fcp.12154. Epub 2015 Oct 7.

PMID:
26392328
45.

Inferior Vena Cava Filter and Recurrent Pulmonary Embolism--Reply.

Mismetti P, Laporte S, Meyer G.

JAMA. 2015 Aug 18;314(7):729-30. doi: 10.1001/jama.2015.8012. No abstract available.

PMID:
26284727
46.

Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.

Couturaud F, Sanchez O, Pernod G, Mismetti P, Jego P, Duhamel E, Provost K, dit Sollier CB, Presles E, Castellant P, Parent F, Salaun PY, Bressollette L, Nonent M, Lorillon P, Girard P, Lacut K, Guégan M, Bosson JL, Laporte S, Leroyer C, Décousus H, Meyer G, Mottier D; PADIS-PE Investigators.

JAMA. 2015 Jul 7;314(1):31-40. doi: 10.1001/jama.2015.7046.

PMID:
26151264
47.

[Initial management of venous thromboembolism].

Mismetti P, Bertoletti L.

Rev Prat. 2015 Feb;65(2):193-8. French.

PMID:
25939220
48.

Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial.

Mismetti P, Laporte S, Pellerin O, Ennezat PV, Couturaud F, Elias A, Falvo N, Meneveau N, Quere I, Roy PM, Sanchez O, Schmidt J, Seinturier C, Sevestre MA, Beregi JP, Tardy B, Lacroix P, Presles E, Leizorovicz A, Decousus H, Barral FG, Meyer G; PREPIC2 Study Group.

JAMA. 2015 Apr 28;313(16):1627-35. doi: 10.1001/jama.2015.3780.

PMID:
25919526
49.

Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis.

Hourcade-Potelleret F, Laporte S, Lehnert V, Delmar P, Benghozi R, Torriani U, Koch R, Mismetti P.

Heart. 2015 Jun;101(11):847-53. doi: 10.1136/heartjnl-2014-306691. Epub 2015 Apr 14. Review.

PMID:
25872524
50.

Impairment of quality of life in patients with antiphospholipid syndrome.

Zuily S, Rat AC, Regnault V, Kaminsky P, Mismetti P, Ninet J, Baillet N, Magy-Bertrand N, Pasquali JL, Lambert M, Pasquier E, Lorcerie B, Lecompte T, Guillemin F, Wahl D; TAC(I)T investigators.

Lupus. 2015 Oct;24(11):1161-8. doi: 10.1177/0961203315580871. Epub 2015 Apr 10.

PMID:
25862730

Supplemental Content

Loading ...
Support Center